組み換えワクチンの世界市場

組み換えワクチンの世界市場は2030年までに191億米ドルに達する見込み

2024年に109億米ドルと推定される組み換えワクチンの世界市場は、2024年から2030年にかけてCAGR 9.8%で成長し、2030年には191億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるサブユニット組み換えワクチンは、CAGR 8.3%を記録し、分析期間終了までに106億米ドルに達すると予測されます。Attenuated組み換えワクチンセグメントの成長率は、分析期間中CAGR 12.4%と推定されます。

米国市場は30億米ドルと推定、中国はCAGR13.2％で成長予測

米国の組み換えワクチン市場は、2024年に30億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに38億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.2%と8.6%と予測されています。欧州では、ドイツがCAGR 7.7%で成長すると予測されています。

世界の組み換えワクチン市場- 主要動向と促進要因のまとめ

組み換え技術はワクチン開発とデリバリーをどのように再定義しているか？

遺伝子組換えワクチンプラットフォームは、遺伝子工学を駆使して特異性が高く、安定かつ安全なワクチン抗原の製造を可能にすることで、世界の予防接種事情に革命をもたらしました。従来の不活化ワクチンや弱毒化ワクチンとは異なり、組み換えワクチンは酵母、細菌、哺乳類系などの宿主細胞における選択抗原の発現に依存しており、病原体の再活性化や汚染のリスクを最小限に抑えています。この技術は、HPV、B型肝炎、帯状疱疹など、従来のワクチンが長期的な有効性や安全性を実現できなかった疾患への採用が増加しています。さらに、組換えプラットフォームの柔軟性により、新興病原体への迅速な対応が可能となり、パンデミック対策やアウトブレイク封じ込め戦略に不可欠となっています。

COVID以後、組換えDNA技術、特にmRNAと互換性のある構築物や、遺伝物質を持たずに本来のウイルスを模倣するウイルス様粒子（VLP）への関心が加速しています。世界の公衆衛生イニシアチブは、低資源環境におけるワクチンへのアクセスと接種率を高めるため、耐熱性、針不要、アジュバント強化型組換え製剤の開発を優先しています。これと並行して、組み換えワクチンは、特に抗原特異性と免疫調節が最重要である腫瘍学やアレルゲン減感作において、個別化免疫戦略の中心になりつつあります。研究開発パイプラインの拡充に伴い、組み換えワクチン開発は予防・治療用ワクチンの主流をますます占めるようになると予想されます。

どの疾患セグメントとターゲット集団が採用を牽引しているか？

肝炎、ヒトパピローマウイルス（HPV）、呼吸器合胞体ウイルス（RSV）、インフルエンザの各分野で、組み換えワクチンの勢いが最も強いです。特に東南アジアやサハラ以南のアフリカでは、国の予防接種プログラムに組換えB型肝炎ワクチンが広く採用され、慢性感染症やそれに伴う肝臓がんが大幅に減少しています。学校ベースのプログラムにHPVワクチンが組み込まれたことで、青少年や若年成人の組換えワクチン使用が促進されています。さらに、高齢者や妊婦に対するRSVワクチンの導入は、特に組換え型製剤の導入により、ライフコースに応じた予防接種アプローチの重要性が高まっていることを示しています。

小児集団、免疫不全者、老年人口は、遺伝子組換えワクチンの優先接種対象として浮上しています。これらの集団は、その優れた安全性プロファイルと有害事象リスクの低減により、組換え製剤から利益を得ています。さらに、組換え腫瘍関連抗原を利用した腫瘍ワクチンが急速に臨床開発されており、治療への応用へのシフトを示唆しています。官民のパートナーシップ、GAVIの支援、WHOの事前承認により、組み換えワクチンが発展途上国の定期予防接種スケジュールに組み込まれつつあります。世界のワクチン接種戦略が小児期に焦点を当てたものから進化するにつれ、組み換えワクチンは、抗菌剤耐性の低減やがん予防など、より広範な公衆衛生の目標に取り組む態勢を整えています。

主要なサプライチェーンと規制上のイネーブラーとは？

製造のスケーラビリティと工程管理は、組み換えワクチンの商業化の成功に不可欠です。従来の卵ベースの方法とは異なり、組換えプラットフォームは、より予測可能な収量、製造期間の短縮、バイオセーフティの強化を提供します。大手メーカーは、シングルユースバイオリアクターシステム、自動精製プロセス、コールドチェーンの革新に投資し、世界の流通をサポートしています。さらに、組換えワクチン製造のモジュール化された性質は、新たな疾病ターゲットに迅速に適応できる多病原性プラットフォームを可能にし、将来の健康危機に対する回復力を支えています。

規制面では、組み換えワクチンは、米国FDA、EMA、およびニーズの高い予防接種製品を優先する世界の規制機関において、加速化されたパスウェイの恩恵を受けています。組み換えワクチンがWHOの緊急使用リストに掲載されたことで、迅速な各国での認可と並んで、アウトブレイク時の迅速な展開への道が開かれつつあります。さらに、ファーマコビジランスの枠組みや市販後調査から得られた実際のエビデンスは、組換え製剤の安全性と有効性のプロファイルを継続的に強化しています。開発・製造受託機関（CDMO）との提携は、バイオテクノロジーのイノベーターが能力のギャップを埋め、世界の需要の高まりに対応するために組み換えワクチンの生産を拡大するのをさらに後押ししています。

この市場の持続的成長の原動力は何か？

組み換えワクチン市場の成長の原動力となっているのは、いくつかの要因です。特に、精密な予防接種に対する世界の関心の高まり、ライフコースに応じたワクチン接種戦略の拡大、ワクチンで予防可能な疾患の発生率の上昇などが挙げられます。ヘルスケアシステムが予防接種プログラムの有効性、安全性、利用しやすさを向上させようとしている中、組換え技術は科学的に検証され、商業的に拡張可能なソリューションを提供しています。全年齢層への普遍的なワクチン接種へのシフトは、政府機関やドナー機関の支援と相まって、日常的な予防接種と発生時対応の両方の場面で需要を加速させています。

技術革新もまた、成長の大きな起爆剤となっています。リコンビナントタンパク質の発現、ナノ粒子送達システム、熱安定化技術の進歩により、農村部や十分なサービスを受けていない地域にもワクチンが行き渡るようになりつつあります。次世代アジュバントや粘膜投与法への継続的な投資により、組み換えワクチンの免疫原性と患者受容性がさらに向上しています。さらに、COVID-19 mRNAワクチンの成功は、組換えプラットフォームに対する世界の信頼を高め、新興感染症やがんとの闘いにおけるその可能性を検証しました。

製薬企業が持続可能なワクチン生産と公平なアクセスを優先する中、組換えワクチン技術は、将来に備えた予防接種エコシステムのバックボーンになりつつあります。新たな適応症、より広範な規制当局の支援、中所得国でのヘルスケア投資の増加により、市場の拡大はさらに加速すると予想されます。

セグメント

ワクチンの種類（サブユニット、急性化、ベクター）、疾患（肺炎球菌、がん、 B型肝炎、インフルエンザ、 DPT、その他の疾患）、流通チャネル（病院および小売薬局、政府供給業者）

調査対象企業の例

• AbbVie Inc.
• AstraZeneca plc
• Bavarian Nordic
• Bharat Biotech
• Clover Biopharmaceuticals
• CSL Limited
• Dynavax Technologies Corporation
• Emergent BioSolutions
• GlaxoSmithKline plc（GSK）
• Green Cross Corporation（GC Biopharma）
• Johnson & Johnson
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Panacea Biotec
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Takeda Pharmaceutical Company Limited
• Vaxart, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Recombinant Vaccines Market to Reach US$19.1 Billion by 2030

The global market for Recombinant Vaccines estimated at US$10.9 Billion in the year 2024, is expected to reach US$19.1 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2024-2030. Subunit Recombinant Vaccines, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$10.6 Billion by the end of the analysis period. Growth in the Attenuated Recombinant Vaccines segment is estimated at 12.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 13.2% CAGR

The Recombinant Vaccines market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Recombinant Vaccines Market - Key Trends & Drivers Summarized

How Are Recombinant Technologies Redefining Vaccine Development and Delivery?

Recombinant vaccine platforms have revolutionized the global immunization landscape by enabling the production of highly specific, stable, and safe vaccine antigens using genetic engineering. Unlike traditional inactivated or live-attenuated vaccines, recombinant vaccines rely on the expression of select antigens in host cells such as yeast, bacteria, or mammalian systems, minimizing the risk of pathogen reactivation or contamination. This technology is increasingly adopted for diseases where traditional vaccines have failed to deliver long-term efficacy or safety, including HPV, hepatitis B, and shingles. Moreover, the flexibility of recombinant platforms allows for rapid response to emerging pathogens, making them vital in pandemic preparedness and outbreak containment strategies.

The post-COVID era has ushered in an acceleration of interest in recombinant DNA technologies, particularly in mRNA-compatible constructs and virus-like particles (VLPs) that mimic native viruses without carrying genetic material. Global public health initiatives are prioritizing the development of thermostable, needle-free, and adjuvant-enhanced recombinant formulations to boost vaccine access and coverage in low-resource settings. In parallel, recombinant vaccines are becoming central to personalized immunization strategies, especially in oncology and allergen desensitization, where antigen specificity and immune modulation are paramount. As R&D pipelines expand, recombinant vaccine development is expected to increasingly dominate the prophylactic and therapeutic vaccine landscape.

Which Disease Segments and Target Populations Are Driving Adoption?

The strongest momentum for recombinant vaccines is being observed in hepatitis, human papillomavirus (HPV), respiratory syncytial virus (RSV), and influenza segments. Widespread adoption of recombinant hepatitis B vaccines in national immunization programs, especially in Southeast Asia and Sub-Saharan Africa, has significantly reduced chronic infections and associated liver cancers. The inclusion of HPV vaccines in school-based programs is propelling recombinant vaccine usage among adolescents and young adults. Additionally, RSV vaccine rollouts for older adults and pregnant women-especially with the introduction of recombinant formulations-highlight the growing importance of life-course immunization approaches.

Pediatric populations, immunocompromised individuals, and geriatrics are emerging as high-priority targets for recombinant vaccine delivery. These groups benefit from recombinant formulations due to their superior safety profiles and reduced risk of adverse events. Furthermore, oncology vaccines leveraging recombinant tumor-associated antigens are under rapid clinical development, signaling a shift toward therapeutic applications. Public-private partnerships, GAVI support, and WHO prequalification are catalyzing recombinant vaccine inclusion in routine immunization schedules in developing countries. As global vaccination strategies evolve beyond childhood focus, recombinant vaccines are poised to address broader public health goals, including antimicrobial resistance reduction and cancer prevention.

What Are the Key Supply Chain and Regulatory Enablers?

Manufacturing scalability and process control are essential to the success of recombinant vaccine commercialization. Unlike traditional egg-based methods, recombinant platforms offer more predictable yields, reduced production timelines, and enhanced biosafety. Leading manufacturers are investing in single-use bioreactor systems, automated purification processes, and cold chain innovations to support global distribution. Additionally, the modular nature of recombinant vaccine production allows for multi-pathogen platforms that can be swiftly adapted to new disease targets, supporting resilience in future health crises.

From a regulatory standpoint, recombinant vaccines are benefitting from accelerated pathways in the U.S. FDA, EMA, and global regulatory bodies that prioritize high-need immunization products. The inclusion of recombinant vaccines in WHO’s emergency use listings, alongside expedited national licensing, is paving the way for rapid deployment during outbreaks. Moreover, pharmacovigilance frameworks and real-world evidence from post-marketing surveillance are continuously reinforcing the safety and efficacy profiles of recombinant products. Partnerships with contract development and manufacturing organizations (CDMOs) are further helping biotech innovators bridge capability gaps and scale recombinant vaccine production to meet growing global demand.

What Is Fueling the Sustained Growth of This Market?

The growth in the recombinant vaccines market is driven by several factors, most notably the increasing global focus on precision immunization, the expansion of life-course vaccination strategies, and the rising incidence of vaccine-preventable diseases. As healthcare systems seek to improve the efficacy, safety, and accessibility of immunization programs, recombinant technologies offer a scientifically validated and commercially scalable solution. The shift toward universal vaccination across all age groups, combined with governmental and donor agency support, is accelerating demand in both routine and outbreak response settings.

Technological innovation is also a major growth catalyst. Advancements in recombinant protein expression, nanoparticle delivery systems, and thermostabilization techniques are extending the reach of vaccines to rural and underserved areas. Continued investment in next-generation adjuvants and mucosal delivery methods is further enhancing the immunogenicity and patient acceptability of recombinant vaccines. Furthermore, the success of COVID-19 mRNA vaccines has increased global trust in recombinant platforms and validated their potential in combating emerging infectious diseases and cancer.

As pharmaceutical companies prioritize sustainable vaccine production and equitable access, recombinant vaccine technologies are becoming the backbone of future-ready immunization ecosystems. Market expansion is expected to intensify with new indications, broader regulatory support, and rising healthcare investments across middle-income nations.

SCOPE OF STUDY:

The report analyzes the Recombinant Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines); Disease (Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease, Other Diseases); Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Inc.
• AstraZeneca plc
• Bavarian Nordic
• Bharat Biotech
• Clover Biopharmaceuticals
• CSL Limited
• Dynavax Technologies Corporation
• Emergent BioSolutions
• GlaxoSmithKline plc (GSK)
• Green Cross Corporation (GC Biopharma)
• Johnson & Johnson
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Panacea Biotec
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Takeda Pharmaceutical Company Limited
• Vaxart, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Recombinant Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Global Focus on Pandemic Preparedness Throws the Spotlight on Recombinant Vaccine Technologies
  • Surging Demand for Safe and Stable Vaccines Propels Growth in Recombinant Vaccine Adoption
  • Rising Incidence of Zoonotic and Emerging Infectious Diseases Drives Innovation in Recombinant Platforms
  • Rapid Antigen Design Capabilities Strengthen Business Case for Recombinant DNA and Protein Vaccines
  • Success of mRNA and Recombinant COVID-19 Vaccines Expands Addressable Market for Advanced Platforms
  • Cost-Effective Manufacturing and Scalability Spur Demand for Recombinant Vaccine Technologies
  • Expansion of Veterinary and Aquaculture Immunization Programs Generates Demand for Recombinant Vaccines
  • Global Immunization Campaigns Supported by WHO and GAVI Accelerate Adoption of Recombinant Products
  • Cross-Platform Compatibility With Adjuvants and Vectors Enhances Flexibility of Recombinant Vaccine Development
  • Rise in Travel-Associated Infections Spurs Demand for Broad-Spectrum Recombinant Vaccines
  • Advancements in Yeast, Bacterial, and Insect Cell Platforms Drive Diversification of Recombinant Pipelines
  • Increased Focus on Non-Invasive Delivery Systems Strengthens Business Case for Oral Recombinant Vaccines
  • Use of AI in Epitope Prediction and Antigen Design Expands Customization Opportunities in Recombinant Vaccines
  • R&D Partnerships Between Public Health Institutes and Biotech Firms Propel Recombinant Innovation
  • Growing Resistance to Traditional Vaccine Production Methods Supports Adoption of Recombinant Alternatives
  • Integration of Recombinant Antigens in Combination Vaccines Broadens Market Potential
  • Supportive Regulatory Pathways and Accelerated Approvals Expedite Recombinant Vaccine Commercialization
  • Increased Biodefense Funding by Governments Drives Pipeline Expansion for Recombinant Technologies
  • Adoption of Recombinant Flu Vaccines in National Programs Sustains Market Growth Momentum
  • Cold Chain Challenges in Remote Regions Strengthen Preference for Thermostable Recombinant Formulations
  • Surge in Consumer Preference for Non-Animal-Based Vaccines Enhances Market Receptivity
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recombinant Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Subunit Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Subunit Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Subunit Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Attenuated Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Attenuated Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Attenuated Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Vector Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Vector Recombinant Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Vector Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospital & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hospital & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hospital & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Government Suppliers Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Government Suppliers Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Government Suppliers Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pneumococcal Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pneumococcal Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Pneumococcal Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Cancer Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Cancer Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Cancer Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hepatitis B Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hepatitis B Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Hepatitis B Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Influenza Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Influenza Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Influenza Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for DPT Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for DPT Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for DPT Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• JAPAN
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• CHINA
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• EUROPE
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Recombinant Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• FRANCE
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• GERMANY
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Recombinant Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• INDIA
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Recombinant Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Recombinant Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Recombinant Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030
• AFRICA
  • Recombinant Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Recombinant Vaccines by Vaccine Type - Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Recombinant Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines and Vector Recombinant Vaccines for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Recombinant Vaccines by Distribution Channel - Hospital & Retail Pharmacies and Government Suppliers Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Recombinant Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies and Government Suppliers Distribution Channel for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Recombinant Vaccines by Disease - Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Recombinant Vaccines by Disease - Percentage Breakdown of Value Sales for Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease and Other Diseases for the Years 2014, 2025 & 2030

IV. COMPETITION